In a recent study, Ramosetron was just as effective as Ondansetron in minimizing postoperative nausea and vomiting (PONV) incidence, severity, and improving patient satisfaction for PONV prevention within 24 hours of the postoperative period. This randomized controlled trial was undertaken by Sashmita Das et al. to assess the effectiveness of Ramosetron and Ondansetron in preventing PONV following laparoscopic surgeries.

In total, 100 female patients were included for laparoscopic gynecological procedures. Volunteers were segregated into two groups (group R and group O) with 50 patients each. In this prospective, double-blinded, interventional study, 30 minutes prior to the end of operation, group R got Ramosterone 0.3 mg, and group O received Ondansetron 8 mg. Patients were evaluated between 0-2, 2–6, 6–12, and 12–24 hours after surgery.

This study's major endpoint was to compare the effectiveness of a single dose of Ondansetron (8 mg) with a single dose of Ramosetron (0.3 mg) for preventing PONV following general anesthesia during laparoscopic procedures. The secondary endpoints were to record the first PONV episode's occurrence time, the necessity for rescue antiemetics, patient satisfaction levels, and occurrence of any adverse effects.

No comparable difference between O and group R in alleviating PONV incidence was recorded in first 24 hours post- surgery. The total incidence of PONV was 51% in the early postoperative interval (0–6 hours) and 13% in the late-postoperative phase (6–24 hrs), respectively. Group O required more rescue antiemetics than group R, but the variation was not significant statistically. Patient’s satisfaction scores were equivalent for both groups.

The most typical adverse event was headache, reported by 9% of patients. Hence, it was concluded that the antiemetic drugs Ramosetron and Ondansetron exhibit comparable efficacy against PONV prevention.